INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 46h ago
House PTR6h ago
SEC 13F6h ago
Robinhood Chain6h ago

Most active filers · 30d

  1. 01FWFogarty Patrick W0B / 206S206 trades$1.10M
  2. 02Kurtz George0B / 202S202 trades$48.06M
  3. 03SPSaba Capital Management, L.P.67B / 19S · 11 late86 trades$22.22M
  4. 04NYNissan Yitzhak82B / 0S · 79 late82 trades$2.61M
  5. 05ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  6. 06AJAllaire Jeremy0B / 50S50 trades$4.26M
  7. 07Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  8. 08SJSheena Jonathan0B / 45S45 trades$3.01M
  9. 09CMCannon-Brookes Michael35B / 0S35 trades$11.72M
  10. 10SLSpeiser Michael L0B / 35S35 trades$14.00M

Cluster activity · 60d

  1. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  2. BUYMTDRMatador Resources CoNov 5 – Nov 189 insiders$1.02M
  3. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  4. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  5. SELLMGNIMAGNITE, INC.Nov 5 – Nov 198 insiders$2.81M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  8. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M

Form 4 transactions

74,191 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
AT
Arora TarunChief Accounting Officer
RNGRingCentral, Inc.
Open-market sale · 10b5-1 plan
SELL$24K
882 sh
Nov 13, 2025Nov 14, 2025
Page 1811 of 1855
← PrevNext →
traded Nov 13, 2025
+1d
SEC Form 4

Evidence

4
HX
Hao XinyanChief Operating Officer
GCTGigaCloud Technology Inc
Open-market sale · 10b5-1 plan
SELL$913K
30.0K sh
Nov 14, 2025Nov 14, 2025
traded Nov 14, 2025
+0dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$455K
1,013 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
VM
Venturo Brian MDirector, Chief Strategy Officer
CRWVCoreWeave, Inc.
Derivative conversion · 10b5-1 plan
C—
1.25M sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$665K
1,477 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$293K
654 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
HX
Hao XinyanChief Operating Officer
GCTGigaCloud Technology Inc
Open-market sale · 10b5-1 plan
SELL$683K
21.4K sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$724K
1,599 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
HX
Hao XinyanChief Operating Officer
GCTGigaCloud Technology Inc
Open-market sale · 10b5-1 plan
SELL$281K
8,568 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
HX
Hao XinyanChief Operating Officer
GCTGigaCloud Technology Inc
Open-market sale · 10b5-1 plan
SELL$768K
24.6K sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$400K
881 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1000K
2,218 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

4
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$769K
1,702 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

3
CL
Charlton Rebecca LSVP, Controller & CAO
BKRBaker Hughes Co
Option exercise · 10b5-1 plan
M—
1,526 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

3
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
5,174 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

3
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
3,926 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

3
DB
Dageville BenoitDirector, Founder and Chief Architect
SNOWSnowflake Inc.
Option exercise · 10b5-1 plan
M—
25.0K sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

3
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
31.3K sh
Nov 14, 2025Nov 14, 2025
traded Nov 14, 2025
+0dSEC Form 4

Evidence

2
DB
Dageville BenoitDirector, Founder and Chief Architect
SNOWSnowflake Inc.
Gift · 10b5-1 plan
G—
7,500 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

2
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$63K
3,529 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

2
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$59K
302 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

1
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$89K
195 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

1
HX
Hao XinyanChief Operating Officer
GCTGigaCloud Technology Inc
Open-market sale · 10b5-1 plan
SELL$176K
5,446 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

1
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$119K
261 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

0
VM
Venturo Brian MDirector, Chief Strategy Officer
CRWVCoreWeave, Inc.
Derivative conversion · 10b5-1 plan
C—
281.3K sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
3,529 sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

0
CL
Charlton Rebecca LSVP, Controller & CAO
BKRBaker Hughes Co
Tax withholding · 10b5-1 plan
F$29K
601 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
84.0K sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

0
VM
Venturo Brian MDirector, Chief Strategy Officer
CRWVCoreWeave, Inc.
Derivative conversion · 10b5-1 plan
C—
281.3K sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

0
MH
Meyer Andrew HollmanChief Business Officer
JANXJanux Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$35K
3,333 sh
Nov 14, 2025Nov 14, 2025
traded Nov 14, 2025
+0dSEC Form 4

Evidence

0
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
10.0K sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

0
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
650 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

0
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
15.0K sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

0
RE
Reeve EmmaDirector
PTCTPTC THERAPEUTICS, INC.
Option exercise · 10b5-1 plan
M—
7,333 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

0
MH
Meyer Andrew HollmanChief Business Officer
JANXJanux Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,333 sh
Nov 14, 2025Nov 14, 2025
traded Nov 14, 2025
+0dSEC Form 4

Evidence

0
GY
Greenstreet YvonneDirector, Chief Executive Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$27K
650 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
3,848 sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

0
VM
Venturo Brian MDirector, Chief Strategy Officer
CRWVCoreWeave, Inc.
Derivative conversion · 10b5-1 plan
C—
1.25M sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence

0
RM
Ragosa MarkCHIEF FINANCIAL OFFICER
KNSAKiniksa Pharmaceuticals International, plc
Option exercise · 10b5-1 plan
M—
19.9K sh
Nov 12, 2025Nov 14, 2025
traded Nov 12, 2025
+2dSEC Form 4

Evidence

0
VM
Venturo Brian MDirector, Chief Strategy Officer
CRWVCoreWeave, Inc.
Gift · 10b5-1 plan
G—
1.28M sh
Nov 13, 2025Nov 14, 2025
traded Nov 13, 2025
+1dSEC Form 4

Evidence